Cardiol Therapeutics (CRDL) Depreciation & Amortization (CF) (2020 - 2026)

Cardiol Therapeutics has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $19476.4 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 11.85% year-over-year to $19476.4; the trailing twelve-month figure through Mar 2026 stood at $75051.7 (down 29.27% YoY), and the FY2025 full-year result was $73130.6, down 37.23% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $19476.4, up from $18627.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $34713.7 in Q4 2024, with the low at $17413.2 in Q1 2025.
• Historically, Depreciation & Amortization (CF) has averaged $25730.5 across 5 years, with a median of $26283.3 in 2022.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) rose 27.66% — and 2025, when it tumbled 46.34%.
• Cardiol Therapeutics' Depreciation & Amortization (CF) stood at $27201.3 in 2022, then gained by 23.27% to $33531.5 in 2023, then rose by 3.53% to $34713.7 in 2024, then plunged by 46.34% to $18627.0 in 2025, then rose by 4.56% to $19476.4 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $19476.4 (Q1 2026), $18627.0 (Q4 2025), and $18566.3 (Q3 2025), per Business Quant data.